

sanofi



ESG
appendices



Sanofi ESG Q3 *achievements*

Affordable access


	<i>Ambition</i>	<i>Progress</i> Q3 2023	Q2 2023
Sanofi Global Health	Reach 1.5 million NCD patients by 2026 (cumulative since 2022) and 2 million by 2030	176,473 patients treated in 27 countries 27 active healthcare partnerships in 14 countries 1 investment	123,025 patients treated in 24 countries 25 active healthcare partnerships in 12 countries 1 investment
Vials donations	Donate 100,000 vials a year to treat people with rare diseases, via the Humanitarian Program launched by Sanofi Specialty Care	1,076 patients treated 74,083 vials donated	1,073 patients treated 52,407 vials donated
Global access plans	Develop a Global access plan for all new products to make them available within two years after first launch	8 Global Access plans initiated or developed covering more than 12 indications	6 Global Access plans initiated or developed covering more than 10 indications



Sanofi ESG Q3 *achievements*

R&D for unmet needs

	<i>Ambition</i>	<i>Progress</i> Q3 2023	Q2 2023
Sleeping sickness	Develop and supply innovative treatments to support the elimination of sleeping sickness by 2030	Data updated annually, next update in Q2 2024	1.5 million patients tested in 2022 837 patients treated in 2022
Polio	Provide inactivated polio vaccines (IPV) to UNICEF for GAVI countries to support polio eradication efforts	23.7 million IPV doses supplied to UNICEF for GAVI countries	18.8 million IPV doses supplied to UNICEF for GAVI countries
Pediatric cancer treatment development	Develop innovative treatments to eliminate cancer death in children	2 assets in protocol preparation for clinical study 2 external collaboration contracts with the pediatric ITCC consortium established	2 assets in protocol preparation for clinical study 2 external collaboration contracts with the pediatric ITCC consortium established



Figures presented are YTD.

Sanofi ESG Q3 *achievements*

Planet Care

	<i>Ambition</i>	<i>Progress</i>	
		Q3 2023	Q2 2023
Climate change - carbon footprint CO2 emissions	55% reduction in scope 1&2 greenhouse gas emissions (CO2 equivalent) by 2030 (cumulative vs. 2019 baseline) to contribute to carbon neutrality by 2030 and net zero emissions by 2045 (all scopes)	35.0% GHG reduction vs 2019	32.6% GHG reduction vs. 2019
Renewable electricity	100% of renewable electricity in all our sites by 2030	72.0%	67.2%
Eco-car fleet	100% carbon neutral car fleet in 2030	39.8% eco fleet	36.5% eco fleet
Blister free syringe vaccines	100% blister free syringe vaccines by 2027(updated annually)	Data updated annually, next update in Q4 2023	33% of blister free syringe produced in 2022
Eco-design	All new products to be eco-designed by 2025	8 LCAs completed & 7 in progress (new and marketed products)	7 LCAs completed & 4 in progress (new and marketed products)



Figures presented are YTD.

Sanofi ESG Q3 *achievements*

In and beyond the workplace

	<i>Ambition</i>	<i>Progress</i> Q3 2023	Q2 2023
Gender balance	Ambition of 50% of women in senior leaders by 2025	43.3%	42.4%
	Ambition of 40% of women in executive posts by 2025	39.3%	38.0%
Engagement with communities	Engage socially and economically with all communities where we operate	5,905 volunteers 36,746 hours	2,883 volunteers 18,103 hours
From Leaders to Citizens	100% of Sanofi leaders have CSR in their development path	69% of the leaders have completed the eLearning phase 18% of the leaders have completed the full program	68% of the leaders have completed the eLearning phase 12% of the leaders have completed the full program



Figures presented are YTD.

Sanofi ESG ratings

Rating agencies

SCORE	SCORE	SCORE	SCORE	SCORE	SCORE	SCORE	SCORE	SCORE
87/100	21.5 Medium risk	78/100	A	Climate Change: A Water: A-	B	4.5/5	3.47/5	65/100
▲ 86/100	▼ 21.2	▲ 71/100	= A	= ▼ A/A	= B	▲ 4.3/5	= 3.47/5	▲ 64/100
One of the highest scores across all sectors globally 81 points for its solid fundamentals & strong preparedness opinion of 6 points	17 th among 419 pharmaceutical companies	Percentile of 98 within 344 scored companies in the industry	Score stable since 2021	Leading position	1 st decile of the 476 companies in the industry	With very high rating across the 3 pillars ESG	Top 10 company	1 st pharmaceutical company out of 57 Score improving since 2018

▲ vs. previous rating
=

Scores assigned by the rating agencies are not equivalent.